Cargando…
A New Approach to Psychiatric Drug Approval in Europe
Corrado Barbui and Irene Bighelli question the current rules governing registration of new medicines in Europe, using the example of psychiatric drugs, and argue that the concept of absolute efficacy should be replaced by the concept of added value whereby evidence from studies comparing a new produ...
Autores principales: | Barbui, Corrado, Bighelli, Irene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797138/ https://www.ncbi.nlm.nih.gov/pubmed/24143137 http://dx.doi.org/10.1371/journal.pmed.1001530 |
Ejemplares similares
-
Europe Needs a Central, Transparent, and Evidence-Based Approval Process for Behavioural Prevention Interventions
por: Faggiano, Fabrizio, et al.
Publicado: (2014) -
Challenges in Developing Evidence-Based Recommendations Using the GRADE Approach: The Case of Mental, Neurological, and Substance Use Disorders
por: Barbui, Corrado, et al.
Publicado: (2010) -
New Methodology for Estimating the Burden of Infectious Diseases in Europe
por: Kretzschmar, Mirjam, et al.
Publicado: (2012) -
New Approaches to Filling the Gap in Tuberculosis Drug Discovery
por: Casenghi, Martina, et al.
Publicado: (2007) -
New era of drug innovation in China
por: Ye, Xuan, et al.
Publicado: (2019)